Impact Biomedical (IBO) Total Current Liabilities (2022 - 2026)

Impact Biomedical (IBO) has reported Total Current Liabilities for 5 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 91.17% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (down 91.17% YoY), and the FY2025 full-year result was $1.2 million, down 88.12% from the prior year.
• Total Current Liabilities rose to $2.0 million in Q2 2026 per IBO's latest filing, from $1.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $23.8 million in Q3 2025 and bottomed at $1.1 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $10.7 million across 5 years, with a median of $11.3 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities surged 1990.77% in 2025, then sank 91.17% in 2026.
• Over 5 years, Total Current Liabilities stood at $10.6 million in 2022, then grew by 24.01% to $13.1 million in 2023, then slipped by 25.51% to $9.8 million in 2024, then slumped by 88.12% to $1.2 million in 2025, then soared by 75.99% to $2.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.0 million, $1.7 million, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.